Sio Capital Management LLC purchased a new position in shares of Epizyme Inc (NASDAQ:EPZM) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 72,826 shares of the biopharmaceutical company’s stock, valued at approximately $1,293,000. Epizyme accounts for approximately 0.8% of Sio Capital Management LLC’s investment portfolio, making the stock its 25th largest holding. Sio Capital Management LLC owned about 0.10% of Epizyme as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Epizyme in the 1st quarter valued at $111,000. Principal Financial Group Inc. bought a new stake in shares of Epizyme in the 1st quarter valued at about $187,000. Teacher Retirement System of Texas bought a new stake in shares of Epizyme in the 4th quarter valued at about $202,000. Element Capital Management LLC acquired a new position in Epizyme in the 1st quarter valued at about $207,000. Finally, Bailard Inc. acquired a new position in shares of Epizyme during the 4th quarter worth approximately $251,000. Institutional investors own 85.22% of the company’s stock.
Shares of NASDAQ EPZM opened at $13.55 on Friday. The firm has a market capitalization of $920.71 million, a price-to-earnings ratio of -6.22 and a beta of 2.09. Epizyme Inc has a 12 month low of $11.15 and a 12 month high of $21.40.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.05. During the same quarter in the previous year, the company earned ($0.56) EPS. sell-side analysts predict that Epizyme Inc will post -2.22 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target (down previously from $26.00) on shares of Epizyme in a report on Wednesday, March 14th. SunTrust Banks reaffirmed a “buy” rating and set a $27.00 price target on shares of Epizyme in a research note on Wednesday, March 14th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research report on Monday, May 21st. Roth Capital set a $24.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Tuesday, April 24th. Finally, Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $23.00.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.